To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01125176
Title Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Acronym ThRiL
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Weill Cornell Medical College New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field